Medicamentos na Prática Clinica - Barros - 1ed-285

Prévia do material em texto

286 Elvino Barros, Helena M. T. Barros & Cols. 
TABELA 20.3 
Tempo de ação e posologia das insulinas 
Tipo Início Pico Duração Posologia Aspecto 
Ultrarrápida 
Lispro 5-15 min 30-90 min 
Aspart 5-15 min 30-90 min 
Glulisina 5-15 min 30-90 min 
Rápida 
Regular 30-60 min 2-3 h 
Lenta 
NPH 2-4 h 4-10 h 
Ultra lenta 
Glargina 2-4 h • sem pico 
Detemir 2-4 h 
• sem pico 
REFERÊNCIAS 
American Diabetes Association. Standards of medi-
cal care in diabetes. Diabetes Care. 2009;32(suppl 
l):S13-61. 
Amori RE, Lau J, Pittas AG. Efficacy and safety of in-
cretin therapy in type 2 diabetes: systematic review 
and meta-analysis. JAMA. 2007;298(2):194-206. 
Bailey CJ and Turner RC. Metformin. N Engl J Med. 
1996;334(9):574-9. 
Blickle JF. Meglitinide analogues: a review of clini-
ca! data focused on recent trials. Diabetes Metab. 
2006;32(2):113-20. 
Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, 
Marinopoulos S, et al. Systematic review: com-
parative effectiveness and safety of oral medica-
tions for type 2 diabetes mellitus. Ann Intern Med. 
2007;147(6):386-99. 
Charbonnel B, Dormandy J, Erdmann E, Massi-Be-
nedetti M, Skene A; PRO active Study Group. The 
prospective pioglitazone clinica! trial in macrovas-
cular events (PROactive): can pioglitazone reduce 
cardiovascular events in diabetes? Study design and 
baseline characteristics of 5238 patients. Diabetes 
Care. 2004 Jul;27(7):1647-53. 
Chia CW, Egan JM. lncretin-based therapies in 
type 2 diabetes mellitus. J Clin Endocrinol Metab. 
2008;93(10):3703-16. 
Chiarelli F, Di Marzio D. Peroxisome proliferator-ac-
tivated receptor-gamma agonists and diabetes: cur-
rent evidence and future perspectives. Vasc Health 
Risk Manag. 2008;4(2):297-304. 
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Ka-
rasik A, Laakso M, et al. Acarbose for prevention of 
type 2 diabetes mellitus: the STOP-NIDDM randomi-
sed trial. Lancet. 2002 Jun 15;359(9323):2072-7. 
4-6 h nas refeições crista lina 
4-6 h crista lina 
4-6 h crista lina 
8-10 h nas refeições crista lina 
12-18 h 1-3x/dia turva 
20-24 h 1-2x/dia crista lina 
6-24 h crista lina 
Chiasson JL, Josse RG, Gomis R, Palmason C, Rodger 
Nw, Ross SA, et al. The efficacy of acarbose in the 
treatment of patients with non-insulin-dependent 
diabetes mellitus. A multicenter controlled clinica! 
trial. Ann Intern Med. 1994;121(12):928-35. 
Dormandy JA, Charbonnel B, Eckland DJA, Erd-
mann E, Massi-Benedetti M, Moules IK, et al. Secon-
dary prevention of macrovascular events in patients 
with type 2 diabetes in the PROactive Study (PROs-
pective pioglitAzone Clinica! Trial ln macroVascu-
lar Events): a randomised controlled trial. Lancet. 
2005;366(9493) :1279-89. 
Edelman S V. Optimizing diabetes treatment using 
an amylin analogue. Diabetes Educ. 2008;34(Suppl 
1):4S-10S. 
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, 
Brodows RG, et al. Exenatide versus insulin glargine 
in patients with suboptimally controlled type 2 dia-
betes. Ann Inter Med. 2005;143(8):559-569. 
Kahn SE, Haffner SM, Heise MA, Herman WH, Hol-
man RR, Jones NP, et al. Glycemic durability of rosi-
glitazone, metformin, or glyburide monotherapy. N 
Engl J Med. 2006;355(23):2427-43. 
Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, 
Donker AJ, et al. Long-term effects of metformin on 
metabolism and microvascular and macrovascular 
disease in patients with type 2 diabetes mellitus. 
Arch Intem Med. 2009;169(6):616-25. 
Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug 
information handbook international. 17th ed. Ohio: 
Lexi-Comp; 2008-2009. 
Li C, Xia J, Zhang G, Wang L. Nateglinide versus re-
paglinide for type 2 diabetes mellitus in China. Acta 
Diabetol. 2009; 46( 4) :325-33. 
Loke YK, Singh S, Furberg CD. Long-term use of 
thiazolidinediones and fractures in type 2 diabetes: 
a meta-analysis. CMAJ. 2009;180(1):32-9.